Rescuing the last-line polymyxins: achievements and challenges
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections
In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
Colistin: an update on the antibiotic of the 21st century
S Biswas, JM Brunel, JC Dubus… - Expert review of anti …, 2012 - Taylor & Francis
The emergence of multidrug-resistant Gram-negative bacteria that cause nosocomial
infections is a growing problem worldwide. Colistin was first introduced in 1952 and was …
infections is a growing problem worldwide. Colistin was first introduced in 1952 and was …
Pharmacology of polymyxins: new insights into an 'old'class of antibiotics
Increasing antibiotic resistance in Gram-negative bacteria, particularly in Pseudomonas
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global …
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global …
[HTML][HTML] Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli
L Scudeller, E Righi, M Chiamenti, D Bragantini… - International journal of …, 2021 - Elsevier
Background: The superiority of combination therapy for carbapenem-resistant Gram-
negative bacilli (CR-GNB) remains controversial. In vitro models may predict the efficacy of …
negative bacilli (CR-GNB) remains controversial. In vitro models may predict the efficacy of …
[HTML][HTML] Colistin: new lessons on an old antibiotic
D Yahav, L Farbman, L Leibovici, M Paul - Clinical microbiology and …, 2012 - Elsevier
Colistin has been re-introduced into clinical practice for the treatment of carbapenem-
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Our objective was to examine the evidence of in vitro synergy of polymyxin-carbapenem
combination therapy against Gram-negative bacteria (GNB). A systematic review and meta …
combination therapy against Gram-negative bacteria (GNB). A systematic review and meta …
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
The polymyxin antibiotics [colistin and polymyxin B (PMB)] are increasingly used as a last-
line option for the treatment of infections caused by extensively drug-resistant Gram …
line option for the treatment of infections caused by extensively drug-resistant Gram …
Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development
MH Abdul-Aziz, J Lipman, JW Mouton… - … in respiratory and …, 2015 - thieme-connect.com
The recent surge in multidrug-resistant pathogens combined with the diminishing antibiotic
pipeline has created a growing need to optimize the use of our existing antibiotic …
pipeline has created a growing need to optimize the use of our existing antibiotic …
Pharmacokinetics and pharmacodynamics of 'old'polymyxins: what is new?
'Old'colistin and polymyxin B are increasingly used as last-line therapy against multidrug-
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …